Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

(2011) E. Park et al.   BLOOD

Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies

(2011) L. E. Hogan et al.   BLOOD

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

(2011) M. Kalac et al.   BLOOD

Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas

(2011) Anastasios Stathis et al.   CLINICAL CANCER RESEARCH

Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia

(2011) D J P M Stumpel et al.   LEUKEMIA

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

(2011) D J Morrison et al.   LEUKEMIA

BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia

(2010) J. C. van Galen et al.   BLOOD

Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting

(2010) E. Schafer et al.   BLOOD

Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer

(2010) Xu-Hui Zhang et al.   CANCER BIOLOGY & THERAPY

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression

(2010) Rintaro Noro et al.   CANCER SCIENCE

The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia

(2010) S. Nakamura et al.   CARCINOGENESIS

Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

(2010) Maryam Fouladi et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 Demethylases

(2010) P.-H. Huang et al.   MOLECULAR PHARMACOLOGY

Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study

(2010) Rani E. George et al.   PEDIATRIC BLOOD & CANCER

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts

(2009) Anne Monks et al.   ANTI-CANCER DRUGS

Histone modification patterns and epigenetic codes

(2009) Andreas Lennartsson et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

(2009) M. E. Figueroa et al.   BLOOD

Pro-proliferative FoxM1 is a target of p53-mediated repression

(2009) A M Barsotti et al.   ONCOGENE

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE